TITLE

Industry Pipeline

PUB. DATE
January 2011
SOURCE
Ocular Surgery News;1/25/2011, Vol. 29 Issue 2, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents updates on ophthalmic treatments as of January 25, 2011, including the completion of a phase 2 clinical trial for AzaSite for treating blepharitis by Acucela.
ACCESSION #
58093962

 

Related Articles

  • Industry Pipeline.  // Ocular Surgery News;9/25/2011, Vol. 29 Issue 18, p34 

    This section offers news briefs concerning the U.S. ophthalmic industry including the marketing clearance received by OcuSense from the U.S. Food and Drug Administration (FDA) involving its TearLab Osmolarity System and Test Card, the start of the phase 3 clinical study of investigational drug...

  • Industry Pipeline.  // Ocular Surgery News;11/25/2011, Vol. 29 Issue 22, p41 

    This section offers news briefs related to the ophthalmic business in the U.S. in November 2011 including the Premarket Notification 510(k) application submitted by Freedom Meditech Inc. for its ClearPath DS-120 Lens Fluorescence Biomicroscope, the CE mark approval received by the KS-SP...

  • Industry Pipeline.  // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p38 

    This section offers news briefs on product approvals and clearances. Victus, a femtosecond laser from Bausch + Lomb and Tecnolas Perfect Vision has been granted a Communidad Europa (CE) mark. Merck's Zioptan ophthalmic solution has received approval from the U.S. Food and Drug Adminitration...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2012, Vol. 30 Issue 4, p30 

    This section offers news briefs on ophthalmological products undergoing clinical trials, including the Lasik Xtra corneal cross-linking procedure, the VibeX corneal cross-linking treatment for corneal ectasia after refractive surgery, and AzaSite Plus and DexaSite for blepharitis treatment.

  • Industry Pipeline.  // Ocular Surgery News;10/25/2011, Vol. 29 Issue 20, p64 

    The article covers issues related market approvals and clinical trials within the ophthalmic industry as of October 2011 including the U.S. Food and Drug Administration (FDA) clearance for the TearLab Osmolarity System and Test Card from OcuSense and the phase 3 trials of the EGP-437...

  • Industry Pipeline.  // Ocular Surgery News;4/25/2012, Vol. 30 Issue 8, p56 

    This section offers news briefs from the ophthalmic industry. A continuing education (CE) mark approval has been secured by Bausch + Lomb and Technolas Perfect Vision for femtosecond laser Victus. The U.S. Food and Drug Administration has given clearance to Carl Zeiss Meditec to include new dry...

  • Sustained-release implants on track for retinal vascular disease treatment. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p23 

    The article focuses on the discussion given by doctor Elias Reichel concerning the outcomes of the use of Ozurdex and Iluvien implants for the treatment of retinal vascular disease.

  • Industry Pipeline.  // Ocular Surgery News;1/25/2012, Vol. 30 Issue 2, p36 

    This section offers international news briefs related to ophthalmology in January 2012 including the Conformité Européenne (CE) mark approval received by the Victus femtosecond laser from Bausch + Lomb and Technolas Perfect Vision, the Premarket Notification 510(k) application submitted by...

  • Ophthalmic Business. INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;9/25/2010, Vol. 28 Issue 18, p35 

    This section offers news briefs related to the ophthalmic equipment and ophthalmic drugs industries. A cooperative marketing agreement has been signed by TearLab Corp. and AMO Canada regarding their dry eye care products. SynergEyes has received approval from the U.S. Food and Drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics